Marinus Pharmaceuticals Announces Multiple Presentations at Upcoming Medical Meetings

Rhea-AI Summary

Marinus Pharmaceuticals (Nasdaq: MRNS) has announced that four abstracts regarding ganaxolone for seizure disorders have been accepted for poster presentations at medical meetings in October. The presentations will occur at the 51st Child Neurology Society Annual Meeting in Cincinnati from October 12-15 and the Neocritical Care Society Annual Meeting in San Antonio from October 17-21. Marinus's ganaxolone is FDA-approved for CDKL5 deficiency disorder and is being evaluated for additional seizure disorders through ongoing Phase 3 trials.

Positive

• Four abstracts accepted for presentation at major medical meetings, highlighting ongoing research.
• Ganaxolone is FDA-approved for treating CDKL5 deficiency disorder, demonstrating market validation.
• The potential of ganaxolone is being explored in additional Phase 3 trials for other seizure disorders.

Negative

• None.

RADNOR, Pa.--(BUSINESS WIRE)-- Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that four abstracts have been accepted for poster presentation at upcoming medical meetings in October. Details are as follows:

51^st Child Neurology Society Annual Meeting: October 12-15; Cincinnati, Ohio

Poster #40: “Extended duration ganaxolone treatment for seizures associated with CDKL5 Deficiency Disorder: 1-year minimum open-label extension follow-up”

• Date and time: Thursday, October 13 from 12:30-2:00 p.m. ET and 5:30-7:00 p.m. ET

Poster #62: “Effect of ganaxolone on behaviors in children with the CDKL5 Deficiency Disorder”

• Date and time: Thursday, October 13 from 12:30-2:00 p.m. ET and 5:30-7:00 p.m. ET

Neocritical Care Society 20^th Annual Meeting: October 17-21; San Antonio, Texas

“Pharmacokinetic Study Evaluating Intravenous Ganaxolone Bolus in Healthy Adult Volunteers”

• Date and time: Poster Session 1, October 19 from 4:15-5:15 p.m. CT

“Pharmacodynamic Effects of Intravenous Ganaxolone Bolus in Healthy Adult Volunteers”

• Date and time: Poster Session 1, October 19 from 4:15-5:15 p.m. CT

About Marinus Pharmaceuticals

Marinus is a commercial-stage pharmaceutical company dedicated to the development of innovative therapeutics for seizure disorders. The Company’s commercial product, ZTALMY^® (ganaxolone) oral suspension CV, has been approved by the U.S. FDA for the treatment of seizures associated with CDKL5 deficiency disorder in patients two years of age and older. The potential of ganaxolone is also being studied in other rare seizure disorders, including in Phase 3 trials in tuberous sclerosis complex and refractory status epilepticus. Ganaxolone is a neuroactive steroid GABA_A receptor modulator that acts on a well-characterized target in the brain known to have anti-seizure effects. It is being developed in IV and oral formulations to maximize therapeutic reach for adult and pediatric patients in acute and chronic care settings. For more information visit www.marinuspharma.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20221011005478/en/

Company:

Sasha Damouni Ellis

Vice President, Corporate Affairs & Investor Relations

Marinus Pharmaceuticals, Inc.

sdamouni@marinuspharma.com

Source: Marinus Pharmaceuticals

FAQ

What abstracts were accepted for Marinus Pharmaceuticals (MRNS) at the October medical meetings?

Four abstracts related to ganaxolone have been accepted for presentation, focusing on its effects on seizures associated with CDKL5 Deficiency Disorder.

When and where will the Child Neurology Society Annual Meeting take place for Marinus Pharmaceuticals (MRNS)?

The Child Neurology Society Annual Meeting will be held from October 12-15 in Cincinnati, Ohio.

What is ganaxolone and what disorders is it approved to treat by Marinus Pharmaceuticals (MRNS)?

Ganaxolone is a neuroactive steroid GABA receptor modulator approved by the FDA for treating seizures associated with CDKL5 deficiency disorder.

What other studies is Marinus Pharmaceuticals (MRNS) conducting with ganaxolone?

Marinus is evaluating ganaxolone in Phase 3 trials for tuberous sclerosis complex and refractory status epilepticus.

What are the dates for the Neocritical Care Society Annual Meeting for Marinus Pharmaceuticals (MRNS)?

The Neocritical Care Society Annual Meeting will be from October 17-21 in San Antonio, Texas.